WFH, Sanofi and Sobi for Armenia: Unprecedented Commitment to Build the Humanitarian Aid Program
Scott Williams, VP and Head, Global Public Affairs at Sanofi, shared an honoring post on LinkedIn:
”In 2014, the World Federation of Hemophilia (WFH) put out a call to action to join them and build their Humanitarian Aid (HA) Program into a more sustainable and predictable solution. Sanofi, along with Sobi, responded with an unprecedented commitment – to provide 1 billion IUs of factor therapy over 10 years. This commitment drove other companies to collaborate with the WFH HA Program and together, we empowered the WFH to provide treatment not only for life-saving surgeries but also for acute bleeds and prophylaxis in children.
I have just returned from a Humanitarian Aid visit with the World Federation of Hemophilia to Armenia. It is with humility that I share a look into 5 extraordinary days together.
It was so impactful to see the before and after progress that’s been made over the past 10+ years in Armenia. We saw a strong hemophilia treatment center and integrated multi-disciplinary care team, access to factor therapy, ability to have prophylaxis treatment at home, impactful local patient organization (NMO), and more. Meeting and hearing the stories of patients and families whose lives have been forever transformed truly puts the “human” in the humanitarian program. It is a powerful reminder of the good that can be achieved when we work together with a shared purpose.
At Sanofi, we are working as a committed industry partner with stakeholders across the bleeding disorders community to drive forward comprehensive, patient-centric solutions that go Beyond the Bleed to meaningfully advance the care paradigm. Envisioning a future beyond the bleed lies at the heart of our mission.
I will never be the same after the visit to Armenia with the WFH. The tears, hope, smiles, determination, and perseverance of children and family members living with hemophilia ensured that I will continue to be a deeply committed Rare Ambassador.”
More encouraging stories featured in Hemostasis Today.
-
Aug 14, 2026, 23:18Claire Hills: New Paper on Immune Surveillance and Immune Evasion of Senescent Cells
-
Aug 14, 2026, 23:16Are We Overlooking What Matters Most to Women with Von Willebrand Disease? – RPTH Journal
-
Aug 14, 2026, 23:15Markus Müller: A New Base Editing Approach Targeting PCSK9 to Lower Cholesterol Levels
-
Aug 14, 2026, 23:14Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring
-
Aug 14, 2026, 23:13Bianca Rocca: PRECISE-DAPT Score Identifies Bleeding Risk After CABG in Patients With POAF
-
Aug 14, 2026, 19:04Ravi Kumar: Why Lupus Anticoagulant Predicts Clots, Not Bleeding
-
Aug 14, 2026, 18:53Veli Bakalov: The Number Every Hematologist Should Know in Polycythemia Vera
-
Aug 14, 2026, 18:41Marta Velia Antonini: Can Nitric Oxide Protect the ECMO Circuit Without Systemic Anticoagulation?
-
Aug 14, 2026, 18:30Irina Gontschar: What the Epkinly FDA Review Teaches Us About Sponsor Oversight